# Roluperidone PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/roluperidone

> Roluperidone, sponsored by Minerva Neurosciences, Inc. (NERV), received a complete response letter from the FDA; the decision is dated February 26, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is roluperidone FDA approved?

Not as of November 16, 2026. Roluperidone, sponsored by Minerva Neurosciences, Inc. (NERV), received a complete response letter from the FDA; the decision is dated February 26, 2024. SEC Form 10-Q: "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." [Calendar and source filings](https://sec-api.dev/pdufa/roluperidone)

Source: SEC Form 10-Q, accession 0001193125-26-451797, https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-06. Cite: https://sec-api.dev/pdufa/roluperidone#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | roluperidone |
| Codes | MIN-101 |
| Sponsor | Minerva Neurosciences, Inc. (NERV) https://sec-api.dev/companies/nerv/catalysts |
| Indications | negative symptoms in schizophrenia, [negative symptoms in patients with schizophrenia](https://sec-api.dev/indications/negative-symptoms-in-patients-with-schizophrenia), [Negative Symptoms of Schizophrenia](https://sec-api.dev/indications/negative-symptoms-of-schizophrenia) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Aug 2022: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: negative symptoms in schizophrenia.
- First seen 2025-02-25, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001193125-25-265685): "In August 2022, we submitted a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for our lead product candidate, roluperidone, for the treatment of negative symptoms in schizophrenia." https://www.sec.gov/Archives/edgar/data/1598646/000119312525265685/nerv-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-108840): "In August 2022, we submitted a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for our lead product candidate, roluperidone, for the treatment of negative symptoms in schizophrenia." https://www.sec.gov/Archives/edgar/data/1598646/000095017025108840/nerv-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-069780): "In August 2022, we submitted a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for our lead product candidate, roluperidone, for the treatment of negative symptoms in schizophrenia." https://www.sec.gov/Archives/edgar/data/1598646/000095017025069780/nerv-20250331.htm
- SEC Form 10-K (accession 0000950170-25-026055): "In August 2022, we submitted a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for our lead product candidate, roluperidone, for the treatment of negative symptoms in schizophrenia." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm
- SEC Form 10-K (accession 0000950170-25-026055): "In August 2022, we submitted an NDA to the FDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm

### April 27, 2023: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: negative symptoms in patients with schizophrenia.
- First seen 2025-02-25, last confirmed 2026-03-11.
- SEC Form 10-K (accession 0001193125-26-101117): "On April 27, 2023, the FDA filed our NDA for roluperidone following our request for formal dispute resolution and appeal of the refusal-to-file letter." https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm
- SEC Form 10-K (accession 0000950170-25-026055): "On April 27, 2023, the FDA filed our NDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm
- SEC Form 10-K (accession 0000950170-25-026055): "On April 27, 2023, the FDA filed our NDA for roluperidone following our request for formal dispute resolution and appeal of the refusal-to-file letter." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm

### April 28, 2023: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-02-25, last confirmed 2026-11-06.
- SEC Form 10-Q (accession 0001193125-26-451797): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-339171): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526339171/nerv-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205182): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526205182/nerv-20260331.htm
- SEC Form 10-K (accession 0001193125-26-101117): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-265685): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312525265685/nerv-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-108840): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000095017025108840/nerv-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-069780): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000095017025069780/nerv-20250331.htm
- SEC Form 10-K (accession 0000950170-25-026055): "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm

### February 26, 2024: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-02-25, last confirmed 2025-08-14.
- SEC Form 10-Q (accession 0000950170-25-108840): "On May 8, 2023, we received confirmation from the FDA that the NDA for roluperidone has been assigned a standard review classification, and that the FDA has assigned a Prescription Drug User Fee Act ("PDUFA") goal date of February 26, 2024." https://www.sec.gov/Archives/edgar/data/1598646/000095017025108840/nerv-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-069780): "On May 8, 2023, we received confirmation from the FDA that the NDA for roluperidone has been assigned a standard review classification, and that the FDA has assigned a Prescription Drug User Fee Act ("PDUFA") goal date of February 26, 2024." https://www.sec.gov/Archives/edgar/data/1598646/000095017025069780/nerv-20250331.htm
- SEC Form 10-K (accession 0000950170-25-026055): "On May 8, 2023, we received confirmation from the FDA that the NDA for roluperidone has been filed in accordance with the Appeal Granted letter dated April 27, 2023 and assigned a standard review classification and a Prescription Drug User Fee Act ("PDUFA") goal date of February 26, 2024." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm
- SEC Form 10-K (accession 0000950170-25-026055): "On May 8, 2023, we received confirmation from the FDA that the NDA for roluperidone has been assigned a standard review classification, and that the FDA has assigned a Prescription Drug User Fee Act ("PDUFA") goal date of February 26, 2024." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm
- SEC Form 10-K (accession 0000950170-25-026055): "On May 8, 2023, we received confirmation from the FDA that our NDA for roluperidone had been assigned a standard review classification and a PDUFA goal date of February 26, 2024." https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/nerv-20241231.htm
- SEC Form 10-Q (accession 0001193125-26-451797): "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm

### February 26, 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: negative symptoms in patients with schizophrenia.
- First seen 2025-02-25, last confirmed 2026-11-06.
- SEC Form 10-Q (accession 0001193125-26-451797): "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-451797): "On February 26, 2024, the FDA issued a Complete Response Letter (the "CRL") to our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-339171): "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526339171/nerv-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-339171): "On February 26, 2024, the FDA issued a Complete Response Letter (the "CRL") to our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526339171/nerv-20260630.htm
- SEC prospectus (424B) (accession 0001193125-26-241915): "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526241915/d136925d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-205182): "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526205182/nerv-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-205182): "On February 26, 2024, the FDA issued a Complete Response Letter (the "CRL") to our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526205182/nerv-20260331.htm
- SEC Form 10-K (accession 0001193125-26-101117): "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm
- SEC Form 10-K (accession 0001193125-26-101117): "On February 26, 2024, the FDA issued a CRL to our NDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia." https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm
- SEC Form 10-K (accession 0001193125-26-101117): "On February 26, 2024, the FDA issued a Complete Response Letter (the "CRL") to our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm
- SEC Form 10-K (accession 0001193125-26-101117): "On February 26, 2024, the FDA issued a CRL to our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-265685): "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." https://www.sec.gov/Archives/edgar/data/1598646/000119312525265685/nerv-20250930.htm

### Q2 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-03-11, last confirmed 2026-03-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-101074): "Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027" https://www.sec.gov/Archives/edgar/data/1598646/000119312526101074/d825896dex991.htm

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Negative Symptoms of Schizophrenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07565428 (Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Minerva Neurosciences." https://clinicaltrials.gov/study/NCT07565428

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Negative Symptoms of Schizophrenia.
- First seen 2026-02-03, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07565428 (Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Minerva Neurosciences." https://clinicaltrials.gov/study/NCT07565428
- Press release filed with the SEC (EX-99) (accession 0001193125-26-450877): "We remain focused on execution and on track for topline efficacy data in the second half of 2027."" https://www.sec.gov/Archives/edgar/data/1598646/000119312526450877/d192598dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-450877): "The topline data from Phase A is expected in 2H 2027." https://www.sec.gov/Archives/edgar/data/1598646/000119312526450877/d192598dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-339147): "Topline data from Phase A of the trial is expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348dex991.htm
- SEC Form 8-K (accession 0001193125-26-241930): "The Company continues to expect topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/d119518d8k.htm
- SEC Form 8-K (accession 0001193125-26-034538): "The Company expects topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526034538/d896733d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-450877): "Topline data from Phase A of the trial is expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1598646/000119312526450877/d192598dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-339147): "We remain focused on execution and on track for topline efficacy data in the second half of 2027."" https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205129): "Topline data from the 12-week Phase A portion (i.e., primary efficacy endpoint) of the trial are expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1598646/000119312526205129/d947378dex991.htm
- SEC Form 10-Q (accession 0001193125-26-451797): "The Company expects topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-451797): "We currently expect topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-339171): "The Company expects topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526339171/nerv-20260630.htm

### 2H 2028: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-08-07, last confirmed 2026-11-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-450877): "The topline data from Phase B is expected in 2H 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526450877/d192598dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-339147): "The topline data from Phase B is expected in 2H 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-450877): "Topline data from Phase B of the trial is expected in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1598646/000119312526450877/d192598dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/roluperidone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Roluperidone PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/roluperidone

```bibtex
@misc{secapidev_pdufa_roluperidone_20261116,
  title        = {Roluperidone PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/roluperidone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_roluperidone_20261116","title":"Roluperidone PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/roluperidone","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
